Recombinant human albumin-interferon α2b fusion protein (Hangzhou Jiuyuan Gene Engineering)

重组人血清白蛋白-干扰素α2b融合蛋白（杭州九源基因工程）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human albumin-interferon α2b fusion protein (Hangzhou Jiuyuan Gene Engineering)
Drug Alias NamerHSA-IFNα2b重组人血清白蛋白-干扰素α2b融合蛋白注射液Recombinant human serum albumin-interferon alpha fusion protein (Hangzhou Jiuyuan Gene Engineering)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis CHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaPending
Originator CompaniesHangzhou Jiuyuan Gene Biomedical Co LtdAcademy Of Military Medical Sciences
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesHangzhou Jiuyuan Gene Biomedical Co LtdAcademy Of Military Medical Sciences
Active IndicationsN/A
Inactive IndicationsHepatitis CHepatitis B

Other Information

ATC CodeN/A
Related LinksN/A